Patents by Inventor Augustine T. Osuma

Augustine T. Osuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • INDAZOLONES AS MODULATORS OF TNF SIGNALING
    Publication number: 20180215764
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 2, 2018
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin D. Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine T. Osuma, Anil Vasudevan, Noel S. Wilson
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20180179198
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson
  • NAMPT INHIBITORS
    Publication number: 20170135994
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: May 18, 2017
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20160184282
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: June 30, 2016
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20160184281
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: October 8, 2015
    Publication date: June 30, 2016
    Applicant: ABBVIE INC.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
  • NAMPT inhibitors
    Patent number: 9193723
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • NAMPT inhibitors
    Patent number: 9187472
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 17, 2015
    Assignee: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • Potassium channel modulators
    Patent number: 8609669
    Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: December 17, 2013
    Assignee: AbbVie Inc.
    Inventors: Xiangdong Xu, Jennifer Van Camp, Marc J. Scanio, William H. Bunnelle, Lei Shi, Augustine T. Osuma, David DeGoey, Arturo Perez-Medrano, Sridhar Peddi, Jyoti R. Patel
  • NAMPT INHIBITORS
    Publication number: 20130303508
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 14, 2013
    Applicant: ABBVIE INC.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • NAMPT INHIBITORS
    Publication number: 20130303511
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 14, 2013
    Applicant: AbbVie Inc.
    Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael R. Michaelides, Ramzi F. Sweis, Marina A. Pliushchev, Andy Judd, Todd M. Hansen, Howard R. Heyman
  • Potassium Channel Modulators
    Publication number: 20120122888
    Abstract: Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 17, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Xiangdong Xu, Jennifer Van Camp, Marc J. Scanio, William H. Bunnelle, Lei Shi, Augustine T. Osuma, David DeGoey, Arturo Perez-Medrano, Sridhar Peddi, Jyoti R. Patel